White House: Trump did not receive Eli Lilly obesity drug

Eli Lilly provided an experimental obesity and diabetes drug to an unidentified 79-year-old man through the FDA's compassionate use program, raising questions about the rarity of such exclusive access. The drug, retratrutide, is in late-stage trials and shows promise comparable to bariatric surgery for weight loss. The patient's connection and the circumstances of the access have sparked speculation, but the White House denied any involvement with President Trump receiving the drug.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل